MBRX Stock: Moleculin Biotech, Inc. Stock Price, Analysis & Insights
Get live mbrx stock price $5.12, comprehensive Moleculin Biotech, Inc. stock analysis, charts, news, and expert forecast. Real-time mbrx stock data and investment insights.
Loading chart...
Company Overview
Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses. Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company's flagship immune/transcription modulator is WP1066, which is in Phase I clinical trial for the treatment of brain tumors and pediatric brain tumors, as well as pancreatic cancer and other malignancies. It also develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat glioblastoma multiforme and COVID-19. The company has partnership and collaboration agreements with MD Anderson; Animal Life Sciences, LLC; and WPD Pharmaceuticals Sp z.o.o. Moleculin Biotech, Inc. was incorporated in 2015 and is headquartered in Houston, Texas.
Company Information
- CEO
- Walter V. Klemp
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 17
Contact Information
- Website
- https://www.moleculin.com
- Address
- 5300 Memorial Drive
- Country
- US
Investment Analysis & Business Insights
Investment Highlights
✓ Strong presence in the Healthcare sector with established market position
✓ Higher growth potential with elevated volatility (Beta: 1.58)
Business Model & Strategy
Moleculin Biotech, Inc. operates in the Biotechnology industry, focusing on medical services, pharmaceutical development, and healthcare delivery. Under the leadership of CEO Walter V. Klemp, the company navigates Healthcare sector dynamics while pursuing growth opportunities. The Biotechnology model requires regulatory compliance, research investment, and patient outcomes to maintain competitiveness and drive shareholder value.
Market Position & Competitive Landscape
Moleculin Biotech, Inc. competes in the Biotechnology within the broader Healthcare. With 6.2 million in market capitalization, the company is positioned as a emerging competitor in its sector. The Healthcare is characterized by demographic shifts, regulatory changes, and medical breakthroughs. As a publicly traded company on the NASDAQ Capital Market, Moleculin Biotech, Inc. provides investors with liquidity and transparency while subject to regulatory oversight. Investors evaluating Moleculin Biotech, Inc. should consider industry-specific trends, competitive positioning, and Healthcare sector fundamentals.
Important Investment Considerations
- ⚠All investments carry risk, including potential loss of principal for Moleculin Biotech, Inc. shareholders
- ⚠Market volatility can significantly impact stock price, especially for smaller companies
- ⚠Sector-specific risks in Healthcare may affect company performance
- ⚠Past performance does not guarantee future results for Moleculin Biotech, Inc.
- ⚠Investors should consider how Moleculin Biotech, Inc. fits within their overall portfolio allocation
- ⚠Valuation metrics suggest potential, but require fundamental analysis
Market Cap
6.19M
P/E Ratio
-0.10
Beta
1.58
Investment Analysis & Insights
Key Investment Highlights
- Market Position: Healthcare leader with 6.19M market capitalization
- Trading Volume: 253.87K shares traded today
- Price Range: 52-week range of $4.75 - $91.25
- Exchange: Listed on NASDAQ Capital Market
Financial Metrics
Market Analysis for Moleculin Biotech, Inc.
Moleculin Biotech, Inc. (MBRX) operates in the Biotechnology industry within the Healthcare sector. With a current market capitalization of 6.19M, the company represents a significant player in its market. The stock is currently trading at $5.12 with a positivedaily change of 6.00%.
The company's 17 employee base and presence on the NASDAQ Capital Marketexchange position it as a Healthcare sector leader. Investors should consider the stock's P/E ratio of -0.10, beta of 1.58, and 52-week price range from $4.75 to $91.25when evaluating investment opportunities.
Why Invest in Moleculin Biotech, Inc.?
Strengths
- • Established market presence in Healthcare
- • Strong financial metrics and market position
- • Listed on major exchange (NASDAQ Capital Market)
- • Experienced leadership under Walter V. Klemp
Investment Considerations
- • Monitor sector-specific market trends
- • Track quarterly earnings performance
- • Consider market volatility and beta
- • Evaluate long-term growth potential
Related Healthcare Stocks
About Healthcare Sector
The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.